Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

UNBELIEVABLE: How is vertex pharmaceuticals stock performance compared to other biotech stocks - Caught on Camera

With a market cap of $115.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a leading biotechnology firm based in Boston, best known for its dominance in cystic fibrosis treatments through drugs like Trikafta.

Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and Vertex Pharmaceuticals fits this criterion perfectly. Its market dominance, innovative pipeline, and financial resilience make it a leading player in the biotechnology industry. The company is also a pioneer in advanced therapies, including gene-editing (Casgevy) and non-opioid pain management (JOURNAVX). 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.